Abstract: A method for automatically assessing information processing speed in a test subject is disclosed. In the inventive method, a first qualimetric activity parameter for sensorial transmission, cognition and motoric output activity is determined and a second qualimetric activity parameter for sensorial transmission and motoric output activity is determined. A third qualimetric activity parameter for cognition is determined by comparing the first and the second qualimetric activity parameters to each other, and the information processing speed in the test subject is assessed based on the first, second and third qualimetric activity parameters. The information processing speed can be determined by comparing the determined qualimetric activity parameters to a reference and the subject's cognitive impairment can then be determined from the processing speed. The inventive method can be computer implemented. A mobile device or system for carrying out the disclosed methods is also disclosed.

Abstract: Disclosed is a method for assessing a cognition and movement disease or disorder in a subject. In the method, a qualimetric activity parameter for cognition and/or fine motoric activity measurements is determined from a dataset of measurements obtained from the subject using a mobile device. The qualimetric activity parameter is compared to a reference and the disease or disorder is thereby assessed. A method identifying whether a subject will benefit from a therapy for a cognition and movement disease or disorder is also disclosed. The method can be carried out with a mobile device having a processor, a sensor and a database as well as software that carries out the method. Also disclosed is a system having a mobile device with a sensor and a remote device having a processor and a database and software that carries out the method for assessing a cognition and movement disease or disorder.

Abstract: There is provided a novel vascular endothelial growth factor, herein designated VEGF-X, in addition to the nucleic acid molecule encoding it, a host cell transformed with said vector and compounds which inhibit or enhance angiogenesis. Also provided is the sequence of a CUB domain present in the sequence of VEGF-X which domain itself prevents angiogenesis and which is used to treat diseases associated with inappropriate vascularisation or angiogenesis.